WO2005051450A1 - 細胞増殖抑制フィルム、医療用具および消化器系ステント - Google Patents
細胞増殖抑制フィルム、医療用具および消化器系ステント Download PDFInfo
- Publication number
- WO2005051450A1 WO2005051450A1 PCT/JP2004/017572 JP2004017572W WO2005051450A1 WO 2005051450 A1 WO2005051450 A1 WO 2005051450A1 JP 2004017572 W JP2004017572 W JP 2004017572W WO 2005051450 A1 WO2005051450 A1 WO 2005051450A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- film
- porous structure
- stent
- resin
- cell growth
- Prior art date
Links
- 230000010261 cell growth Effects 0.000 title claims abstract description 75
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 60
- 210000004798 organs belonging to the digestive system Anatomy 0.000 title abstract 4
- 239000011148 porous material Substances 0.000 claims abstract description 87
- 229920005989 resin Polymers 0.000 claims abstract description 58
- 239000011347 resin Substances 0.000 claims abstract description 58
- 238000000034 method Methods 0.000 claims abstract description 36
- 239000000463 material Substances 0.000 claims abstract description 28
- 230000012010 growth Effects 0.000 claims abstract description 3
- 239000000758 substrate Substances 0.000 claims description 46
- 239000003960 organic solvent Substances 0.000 claims description 35
- 239000007788 liquid Substances 0.000 claims description 25
- 238000009833 condensation Methods 0.000 claims description 24
- 230000005494 condensation Effects 0.000 claims description 24
- 238000005266 casting Methods 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 238000001704 evaporation Methods 0.000 claims description 17
- 230000004663 cell proliferation Effects 0.000 claims description 10
- 230000035755 proliferation Effects 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 20
- 201000011510 cancer Diseases 0.000 abstract description 20
- 102000038379 digestive enzymes Human genes 0.000 abstract description 15
- 108091007734 digestive enzymes Proteins 0.000 abstract description 15
- 239000013543 active substance Substances 0.000 abstract description 12
- 230000001079 digestive effect Effects 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 7
- 239000012530 fluid Substances 0.000 abstract description 6
- 239000003966 growth inhibitor Substances 0.000 abstract 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 58
- 239000000243 solution Substances 0.000 description 29
- 102000004882 Lipase Human genes 0.000 description 19
- 108090001060 Lipase Proteins 0.000 description 19
- 239000004367 Lipase Substances 0.000 description 19
- 102000004142 Trypsin Human genes 0.000 description 19
- 108090000631 Trypsin Proteins 0.000 description 19
- 235000019421 lipase Nutrition 0.000 description 19
- -1 polytetrafluoroethylene Polymers 0.000 description 19
- 239000012588 trypsin Substances 0.000 description 19
- 229920000642 polymer Polymers 0.000 description 13
- 239000012085 test solution Substances 0.000 description 13
- 239000011521 glass Substances 0.000 description 12
- 239000011248 coating agent Substances 0.000 description 11
- 238000000576 coating method Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 229910045601 alloy Inorganic materials 0.000 description 10
- 239000000956 alloy Substances 0.000 description 10
- 239000012298 atmosphere Substances 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 230000002093 peripheral effect Effects 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- ZNIFSRGNXRYGHF-UHFFFAOYSA-N Clonidine hydrochloride Chemical compound Cl.ClC1=CC=CC(Cl)=C1NC1=NCCN1 ZNIFSRGNXRYGHF-UHFFFAOYSA-N 0.000 description 8
- 229920001577 copolymer Polymers 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 8
- 239000012466 permeate Substances 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 210000002249 digestive system Anatomy 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 229920002589 poly(vinylethylene) polymer Polymers 0.000 description 7
- 210000000013 bile duct Anatomy 0.000 description 6
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 238000007664 blowing Methods 0.000 description 5
- 201000010175 gallbladder cancer Diseases 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 229920002635 polyurethane Polymers 0.000 description 5
- 239000004814 polyurethane Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000010936 titanium Substances 0.000 description 5
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 229920001400 block copolymer Polymers 0.000 description 4
- 230000005907 cancer growth Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229920006167 biodegradable resin Polymers 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 239000011247 coating layer Substances 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 229920000098 polyolefin Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000004709 Chlorinated polyethylene Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000004581 coalescence Methods 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000879 optical micrograph Methods 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920001707 polybutylene terephthalate Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920006254 polymer film Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 229920003002 synthetic resin Polymers 0.000 description 2
- 239000000057 synthetic resin Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- PEVRKKOYEFPFMN-UHFFFAOYSA-N 1,1,2,3,3,3-hexafluoroprop-1-ene;1,1,2,2-tetrafluoroethene Chemical compound FC(F)=C(F)F.FC(F)=C(F)C(F)(F)F PEVRKKOYEFPFMN-UHFFFAOYSA-N 0.000 description 1
- PYSRRFNXTXNWCD-UHFFFAOYSA-N 3-(2-phenylethenyl)furan-2,5-dione Chemical compound O=C1OC(=O)C(C=CC=2C=CC=CC=2)=C1 PYSRRFNXTXNWCD-UHFFFAOYSA-N 0.000 description 1
- GZVHEAJQGPRDLQ-UHFFFAOYSA-N 6-phenyl-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(C=2C=CC=CC=2)=N1 GZVHEAJQGPRDLQ-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 229910000014 Bismuth subcarbonate Inorganic materials 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 241000209027 Ilex aquifolium Species 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 239000004640 Melamine resin Substances 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229910000566 Platinum-iridium alloy Inorganic materials 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229920000147 Styrene maleic anhydride Polymers 0.000 description 1
- 229910004337 Ti-Ni Inorganic materials 0.000 description 1
- 229910011209 Ti—Ni Inorganic materials 0.000 description 1
- 240000000581 Triticum monococcum Species 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- WAIPAZQMEIHHTJ-UHFFFAOYSA-N [Cr].[Co] Chemical class [Cr].[Co] WAIPAZQMEIHHTJ-UHFFFAOYSA-N 0.000 description 1
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 description 1
- 125000005396 acrylic acid ester group Chemical group 0.000 description 1
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 1
- 229920001893 acrylonitrile styrene Polymers 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229920003180 amino resin Polymers 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- MGLUJXPJRXTKJM-UHFFFAOYSA-L bismuth subcarbonate Chemical compound O=[Bi]OC(=O)O[Bi]=O MGLUJXPJRXTKJM-UHFFFAOYSA-L 0.000 description 1
- 229940036358 bismuth subcarbonate Drugs 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 239000001201 calcium disodium ethylene diamine tetra-acetate Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000003486 chemical etching Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 239000003759 ester based solvent Substances 0.000 description 1
- 229920000840 ethylene tetrafluoroethylene copolymer Polymers 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002458 fetal heart Anatomy 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- KHYBPSFKEHXSLX-UHFFFAOYSA-N iminotitanium Chemical compound [Ti]=N KHYBPSFKEHXSLX-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002700 inhibitory effect on cancer Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000005453 ketone based solvent Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 125000000686 lactone group Chemical group 0.000 description 1
- 229910052745 lead Inorganic materials 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- 229910052758 niobium Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- HWLDNSXPUQTBOD-UHFFFAOYSA-N platinum-iridium alloy Chemical class [Ir].[Pt] HWLDNSXPUQTBOD-UHFFFAOYSA-N 0.000 description 1
- 229920001643 poly(ether ketone) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002285 poly(styrene-co-acrylonitrile) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000306 polymethylpentene Polymers 0.000 description 1
- 239000011116 polymethylpentene Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920005749 polyurethane resin Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- SCUZVMOVTVSBLE-UHFFFAOYSA-N prop-2-enenitrile;styrene Chemical compound C=CC#N.C=CC1=CC=CC=C1 SCUZVMOVTVSBLE-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- YFNCATAIYKQPOO-UHFFFAOYSA-N thiophanate Chemical compound CCOC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OCC YFNCATAIYKQPOO-UHFFFAOYSA-N 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 229920006163 vinyl copolymer Polymers 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/146—Porous materials, e.g. foams or sponges
Definitions
- the present invention relates to a cell growth suppressing film, a cell growth suppressing method using the cell growth suppressing film, a medical device, and an eraser placed in a lumen of a digestive system body such as a bile duct, an esophagus, a duodenum, or a large intestine.
- the present invention relates to a system stent.
- Japanese Patent Application Laid-Open No. 2003-149096 discloses a honeycomb-like film having a specific pore size and a variation in the pore size, formed by the same method as the film described in Japanese Patent Application Laid-Open No. 2002-335949.
- a structured blood filtration membrane is described. This filtration membrane is for removing whole blood leukocytes for transfusion.
- Japanese Patent Publication No. 2001-512354 discloses a coating layer on the surface of a medical device such as a stent.
- a medical device has been proposed in which a bioactive substance capable of suppressing the growth of cancer cells, such as an anticancer agent, is released from this coating layer over time with this coating layer! Puru.
- this medical device has a problem that the physiologically active substance used has a large side effect on the human body and a large burden on the patient.
- JP-A-2001-327609 and the like disclose a covered stent in which a resin film is coated on a stent base material. It is clear that this covered stent is useful for preventing stenosis of the body lumen due to the growth of cancer cells, because the resin film does not allow cancer cells to penetrate!
- the present invention has been made in view of such a situation in the prior art, and exhibits a cell growth inhibitory action without using a physiologically active substance such as an anticancer agent, and constitutes a medical device.
- a stent suitable for providing digestive fluids and digestive enzymes contained in the digestive juices, but not permeating cancer cells, should be provided. The task is to provide.
- the present inventors have proposed an organic solvent for a resin such as 1,2-polybutadiene by a method similar to the method described in the above-mentioned publications (JP-A-2002-335949, JP-A-2003-149096).
- the solution was cast on a substrate to obtain a film having a porous structure of a honeycomb structure.
- this film was placed in a medium and culture of malignant gallbladder cancer cells was attempted on the film, it was unexpectedly contrary to the example for cardiomyocytes described in JP-A-2002-335949. Discovered that the growth of the cancer cells was significantly suppressed.
- a medical device base capable of suppressing the progression of cancer without burdening the patient due to the side effects of the physiologically active substance can be obtained.
- a porous structure is formed by through-holes having a predetermined size and a highly controlled pore diameter! /
- a film made of pulp resin is coated on a stent substrate to constitute a stent.
- a cell growth suppressing film composed of a resin having a porous structure formed at least on a surface portion.
- the porous structure of the cell growth-inhibiting film of the present invention is preferably a honeycomb-like structure.
- the average pore diameter of the pores constituting the porous structure is 0.1 to 100 m, and the variation coefficient of the pore diameter of the pores constituting the porous structure is 30% or less. It is preferable to be there! /
- the cell growth-inhibiting film of the present invention is obtained by casting a solution of a resin in an organic solvent on a substrate, evaporating the organic solvent and causing dew condensation on the surface of the cast solution, and removing fine water droplets generated by the dew condensation. It is preferably a film obtained by evaporation or a stretched film thereof.
- the proliferation of cells at the contact is suppressed.
- a method for suppressing cell growth characterized by the following.
- the porous structure of the film used is preferably a honeycomb structure.
- the coefficient of variation of the pore diameter of the pores constituting the porous structure which preferably has an average pore diameter of 0.1 to 100 m, is preferably 30%. The following is preferred.
- an organic solvent solution of a film resin to be used is cast on a substrate, the organic solvent is evaporated, and condensation is caused on the surface of the cast liquid.
- the film is preferably a film obtained by evaporating fine water droplets generated by the condensation or a stretched film thereof.
- a medical device in which the whole or a part of the surface of the medical device substrate is covered with a resin film having a porous structure formed on at least the surface. Provided.
- the porous structure of the film covering the medical device substrate is preferably a honeycomb-like structure.
- the average diameter of the pores constituting the porous structure of the film covering the medical device substrate is preferably 0.1 to 100 m, and the pore diameter of the pores constituting the porous structure is preferably 0.1 to 100 m.
- the coefficient of variation is 30% or less.
- the film covering the medical device substrate is formed by casting a resin solution of an organic solvent on a substrate, evaporating the organic solvent, and causing condensation on the surface of the cast liquid. And a film obtained by evaporating fine water droplets generated by the condensation or a stretched film thereof is preferable! /.
- a porous structure is formed in the stent base material by through-holes having an average pore diameter of 0.1 to 20 ⁇ m and a variation coefficient of the pore diameter of 30% or less.
- an eraser-based stent characterized by being coated with a film made of fat.
- the porous structure of the film is preferably a honeycomb structure.
- the film casts a resin organic solvent solution on a substrate, evaporates the organic solvent, and causes dew condensation on the surface of the cast organic solvent solution. It is preferably a film obtained by evaporating fine water droplets generated by condensation or a stretched film thereof.
- the stent of the present invention is a biliary stent.
- cell growth-inhibiting action can be exerted without using a physiologically active substance, so that side effects caused by the physiologically active substance can be avoided. Can be.
- FIG. 1 is a sketch drawing of an optical micrograph of a cell growth inhibiting film of the present invention having a honeycomb-like structure.
- the cell growth-inhibiting film of the present invention is characterized by having a porous structure formed at least on the surface thereof and made of resin and exhibiting a cell growth-inhibiting action.
- the cell growth inhibitory action refers to an action of suppressing the growth of cancer cells or tumor cells and an action of killing Z or cells.
- the porous structure is reduced.
- Cells grow normally on a resin film having a normal flat membrane structure without having, whereas when the cell growth suppressing film of the present invention is used, cell growth is significantly suppressed or cells die. .
- the cell growth suppressing film of the present invention is useful as a material for constituting a medical device.
- the cell growth inhibiting film of the present invention only needs to have a porous structure at least on its surface. Further, the holes constituting the porous structure may be either through holes or non-through holes.
- the porous structure is particularly preferably a honeycomb structure.
- the honeycomb-like structure refers to a porous structure in which a plurality of holes having a substantially constant hole diameter are regularly arranged.
- FIG. 1 a sketch of an optical micrograph of a film having a honeycomb structure is shown in FIG.
- each of the pores of the porous structure has a continuous porous structure in which the pores communicate with each other inside the film.
- the average pore diameter of the pores constituting the porous structure is preferably 0.1 to 100 m, and more preferably 0.1 to 20 m. Is more preferably 0.5 to 10 m.
- the hole diameter refers to the diameter of the largest inscribed circle with respect to the opening shape of the hole. For example, when the opening shape of the hole is substantially circular, it refers to the diameter of the circle.
- the shape of the opening of each hole in the porous structure is not particularly limited, and may be any shape such as a circular shape, an elliptical shape, a square shape, a rectangular shape, and a hexagonal shape.
- the thickness of the cell growth-inhibiting film of the present invention is not particularly limited, but is usually 0.1 to 100 ⁇ m, preferably 0.5 to 20 ⁇ m.
- the resin constituting the cell growth-inhibiting film of the present invention is not particularly limited! However, a polymer compound soluble in an organic solvent and having low toxicity is preferred.
- the resin constituting the cell growth-inhibiting film of the present invention includes conjugated gen-based polymers such as polybutadiene, polyisoprene, styrene-butadiene copolymer, acrylonitrile-butadiene-styrene copolymer; poly- ⁇ -proratetaton; A polyamide-based polymer such as cellulose acetate, cenorreoid, cenorellose nitrate, acetinoresenolerose, cellophane, etc., and phenolic high thiopositamide, 6, positive amide, 66, positive amide, 610, positive amide, 612, positive amide, 12, positive amide 46, etc.
- conjugated gen-based polymers such as polybutadiene, polyisoprene, styrene-butadiene copolymer, acrylonitrile-butadiene-styrene copolymer; poly- ⁇ -proratet
- Fluorinated polymers such as polytetrafluoroethylene, polytrifluoroethylene, perfluoroethylene propylene copolymer; polystyrene, styrene ethylene propylene copolymer, styrene ethylene butylene copolymer, styrene Isoprene copolymer, chlorinated polyethylene acrylonitrile styrene copolymer, a methacrylic acid ester-styrene copolymer, styrene acrylonitrile copolymer, scan styrene maleic anhydride copolymers, acrylic acid ester acrylonitrile styrene copolymer Styrene-based polymers such as polymers; polyethylene, chlorinated polyethylene, ethylene ⁇ -olefin copolymer, ethylene vinyl acetate copolymer, ethylene monochloride vinyl copolymer, ethylene acetate butyl cop
- the resin constituting the cell growth-inhibiting film of the present invention either a non-biodegradable resin or a biodegradable resin can be used, but the cell growth-inhibiting action in the living body is maintained for a long time. Aspects are preferably formed from non-biodegradable resins that are not easily degraded in vivo.
- a conjugated gen-based polymer, styrene-based polymer or polyurethane is particularly preferable because a cell growth-inhibiting film having an excellent cell growth-inhibiting action can be obtained.
- the resin constituting the cell growth inhibiting film of the present invention may be supplemented with an amphiphilic substance.
- amphipathic substance to be added examples include a polyethylene glycol-polypropylene glycol block copolymer; an acrylamide polymer having a main chain skeleton, a dodecyl group as a hydrophobic side chain, and a lactone group or a carboxyl group as a hydrophilic side chain.
- Amphiphilic resin ionic complex of anionic polymer such as non-dextran sulfate, nucleic acid (DNA or RNA) and long-chain alkylammonium salt; water-soluble such as gelatin, collagen, albumin Amphiphilic resin with protein as a hydrophilic group; amphiphilic such as polylactic acid-polyethylene glycol block copolymer, poly ⁇ -force prolatatatone polyethylene glycol block copolymer, polymalic acid-polymalic acid alkyl ester block copolymer Sex fat; And the like.
- anionic polymer such as non-dextran sulfate, nucleic acid (DNA or RNA) and long-chain alkylammonium salt
- water-soluble such as gelatin, collagen, albumin
- Amphiphilic resin with protein as a hydrophilic group amphiphilic such as polylactic acid-polyethylene glycol block copolymer, poly ⁇ -force prolatatatone polyethylene glycol block copolymer,
- the cell growth inhibitory film of the present invention exhibits a cell growth inhibitory action without adding a physiologically active substance. Therefore, from the viewpoint of avoiding side effects, it is not necessary to add a bioactive substance having a cell growth inhibitory action. preferable. However, for the purpose of obtaining a stronger cell growth inhibitory action, a physiologically active substance having a cell growth inhibitory action may be added. Even in this case, a sufficient cell growth inhibitory action can be obtained with a smaller amount of addition than before, so that side effects due to the physiologically active substance are reduced.
- the method for producing the cell growth-inhibiting film of the present invention is not particularly limited !, for example, a method in which a solution of a resin in an organic solvent is cast on a substrate, the organic solvent is evaporated, and the surface of the casting liquid is cast. To cause dew condensation, and evaporate minute water droplets generated by the dew condensation.
- a solution of a resin in an organic solvent is cast on a substrate, and the organic solvent is gradually evaporated by blowing high-humidity air, and condensation is formed on the surface of the cast liquid.
- This is a method of evaporating and causing dew condensation on the surface of the casting liquid to evaporate fine water droplets generated by the dew condensation. According to these methods, it is relatively easy to obtain a cell growth inhibiting film having a desired pore size, a pore force having a high uniformity of pore size, and a porous structure having a honeycomb-like structure. it can.
- the above-described method is characterized in that water droplets generated by condensation are used in a shape ⁇ .
- water droplets generated by condensation are used in a shape ⁇ .
- a film having a porous structure that is a continuous porous structure can be obtained.
- the organic solvent used is insoluble in water. Is preferred,.
- organic solvent used examples include halogenated hydrocarbon solvents such as chloroform and methylene chloride; saturated hydrocarbon solvents such as n-pentane, n-xane, and n-heptane; cyclopentane, cyclohexane and the like.
- Alicyclic hydrocarbon solvents such as chloroform and methylene chloride
- saturated hydrocarbon solvents such as n-pentane, n-xane, and n-heptane
- cyclopentane cyclohexane and the like.
- Alicyclic hydrocarbon solvents such as chloroform and methylene chloride
- saturated hydrocarbon solvents such as n-pentane, n-xane, and n-heptane
- cyclopentane cyclohexane and the like.
- Alicyclic hydrocarbon solvents such as chloroform and methylene chloride
- saturated hydrocarbon solvents such as n-pentane,
- organic solvents can be used alone or as a mixed solvent obtained by combining these solvents.
- the concentration of the resin dissolved in the organic solvent is preferably 0.01% to 10% by weight, and more preferably 0.05% to 5% by weight. ⁇ If the resin concentration is lower than 0.01% by weight, the mechanical strength of the obtained film is insufficient, which is not desirable. If the resin concentration is 10% by weight or more, a desired porous structure may not be obtained.
- Cap resin amphiphilic resin
- the amount of the amphiphilic substance to be added is preferably 99: 1 to 50:50 in terms of the weight ratio of the resin to the amphiphilic substance.
- Substrates on which the organic solvent solution of the resin is cast include inorganic substrates such as glass substrates, metal substrates, and silicon substrates; organic substrates composed of high molecules such as polypropylene, polyethylene, and polyether ketone; water, liquid paraffin. And a liquid substrate such as liquid polyether.
- the diameter of the hole is adjusted by adjusting the resin concentration and the amount of the liquid to be cast to support a petri dish or the like.
- the atmosphere supplied to the bed can be controlled by controlling the temperature and Z or humidity of the blowing air and the flow rate of the blowing air, or by controlling the evaporation speed and the Z or condensation speed of the solvent. it can.
- the high-humidity air blown onto the casting liquid may be any humidity that allows the moisture in the air to condense on the surface of the casting liquid, and preferably has a relative humidity of 20 to 100%. % Is more preferable.
- an inert gas such as nitrogen or argon may be used.
- the flow rate of the high-humidity air blown onto the casting liquid may be any flow rate at which moisture in the air can condense on the casting liquid surface and evaporate the solvent used for casting.
- the film thickness is 11-5 LZmin.
- High humidity air is blown for a period of time until the solvent used for casting evaporates and a film is formed, and is usually 160 minutes.
- the temperature of the atmosphere when the high humidity air is blown may be any temperature at which the solvent used for casting can evaporate, but is preferably 5 to 80 ° C.
- a film having a porous structure produced as described above may be used as it is, or a stretched film obtained by stretching this film may be used.
- the method of stretching the film is not particularly limited.
- the film can be stretched by gripping two or more ends of a film having a porous structure and pulling the film in the elongation direction.
- the stretching may be uniaxial stretching, biaxial stretching or triaxial stretching.
- the elongation ratio in the stretching direction is not particularly limited, but is preferably in the range of 1.1 to 10 times.
- the stretching can also be performed by coating the cell growth-suppressing film of the present invention on a medical device substrate and expanding the medical device substrate, as described later. . That is, by extending the medical device base material coated with the cell growth suppressing film of the present invention, a stretched cell growth suppressing film can be obtained.
- the cell growth inhibitory method of the present invention provides a resin having a porous structure at least on its surface. By contacting the surface portion of the strong film, the proliferation of cells in the contact portion is suppressed.
- a film which is preferable as the above-mentioned cell growth suppressing film, is preferably used.
- the medical device of the present invention is characterized in that the whole or a part of the surface of the medical device substrate is covered with a film made of resin whose porous structure is formed at least on the surface.
- the medical device substrate is a force that is a substrate that can be used as a medical device by coating a film, but can be used as a medical device.
- a film used for coating it is preferable to use a film which is preferable as the above-mentioned cell growth suppressing film.
- the medical device of the present invention is coated with a film exhibiting a cell growth inhibitory effect on cancer cells or tumor cells, it can inhibit the progress of cancer by contacting the film with a contact portion. Can be.
- this cell growth inhibitory action is exerted without the need for a physiologically active substance such as an anticancer agent, it is possible to avoid side effects due to the physiologically active substance.
- the medical device of the present invention includes, for example, a stent, a catheter, a medical tube, and the like. It is preferable that the medical device is a stent, in particular, it is indwelled in a body lumen narrowed or occluded by cancer cells or tumor cells. Preferably, it is a stent that is fabricated. Such stents include ureteral stents, biliary stents, airway stents, esophageal stents, colonic stents, etc. Rui-dani device-based stents are particularly preferred.
- the method of coating the medical device substrate with a film is not particularly limited, but is similar to the method of preparing the cell growth-inhibiting film of the present invention. Is preferred.
- the adhesive strength can be obtained only by bringing the prepared film into contact with the surface of the medical device base material.However, if necessary, using a method such as fusion with an adhesive, a solvent, or heat, etc. Is also good.
- As another method of coating a film on a medical device substrate there is a method in which a film is formed on the medical device substrate by applying the above-described method using the medical device substrate as a substrate.
- a porous structure is formed on a stent substrate by through-holes having an average pore diameter of 0.1-20 / zm and a variation coefficient of the pore diameter of 30% or less. It is made by coating a film consisting of
- the film used for coating is a film having a more specific structure among the above-mentioned cell growth suppressing films.
- the through-hole having an average pore size of 0.1 to 20 m, preferably 0.5 to 10 / zm and a variation coefficient of the pore size of 30% or less, preferably 20% or less has a porous structure.
- a film made of a resin on which is formed is particularly preferable that the porous structure of this film is the above-mentioned nonwoven structure.
- the magnitude of 1 X 10- 4 m- 10- 3 m , cancer cells (tumor cells) is a size of about 20 / ZM several hundred / zm.
- the film used in the present invention has an average pore diameter of 0.1 to 20 m, a variation coefficient of the pore diameter of 30% or less, a high uniformity of the pore diameter, and a high through-hole power. It consists of a resin with a structure formed. Therefore, it has the function of permeating digestive enzymes but not permeating cancer cells (tumor cells).
- the average pore size of the pores having a porous structure is less than 0.1 m, it may be difficult to permeate digestive juices and digestive enzymes, and if it exceeds 20 m, cancer cells (tumor cells) may be permeated. is there. Further, if the variation coefficient of the pore diameter of the pores constituting the porous structure exceeds 30%, cancer cells (tumor cells) may be permeated even if the average pore diameter is a predetermined value.
- the porous structure is preferably a continuous porous structure in which adjacent holes communicate with each other inside the film.
- the flow path resistance when the digestive juice passes through the film is reduced, so that the digestive juice has a lower pressure than a film having a porous structure in which adjacent holes do not communicate with each other.
- a digestive juice secreted at a low pressure, such as splenic fluid can efficiently penetrate the film.
- a method for producing a film used in the present invention a method similar to the method for producing a cell proliferation inhibiting film described in the section of the cell proliferation inhibiting film of the present invention is preferable.
- the stent substrate used in the present invention can be used as a stent even if it is a force alone, which is a substrate that can be used as a stent by coating a film.
- the shape of the stent base material is not particularly limited as long as it is a tubular body.
- the stent base material is a tubular body in which a linear body or a band-like body is connected in a network to form a peripheral wall.
- the wire diameter is preferably 0.05 to lmm.
- the width is preferably 0.1 to 10 mm, and the thickness is preferably 0.05 to 5 mm.
- this stent base material as a tubular body varies depending on the size of the body lumen in which it is to be placed, but usually, the outer diameter is 2 to 30 mm, the inner diameter is 1 to 29 mm, and the length is 5 to 5 mm. 200 mm.
- the outer diameter is preferably 5-20 mm, the inner diameter is 419 mm, and the length is preferably 10-100 mm.
- a synthetic resin or a metal is used as a material of the stent base material.
- a synthetic resin having a certain degree of hardness and elasticity is used, and a biocompatible resin is preferable.
- a synthetic resin having a certain degree of hardness and elasticity is used, and a biocompatible resin is preferable.
- the polyolefin include polyethylene and polypropylene
- examples of the polyester include polyethylene terephthalate and polybutylene terephthalate
- examples of the fluorine resin include polytetrafluoroethylene (PTFE) and ethylene / tetrafluoroethylene copolymer. Coalescence (ETFE).
- a superelastic alloy such as a nickel titanium (TiNi) alloy, a force capable of using stainless steel, tantalum, titanium, a cobalt chromium alloy, and the like, particularly a superelastic alloy is preferable.
- the mechanical properties of the superelastic alloy can be appropriately changed by selecting the working ratio and the Z or the conditions of the final heat treatment.
- the molding of the stent base material includes, for example, laser processing (for example, YAG laser), electric discharge processing. It can be performed by cutting the pipe by chemical etching, cutting, or the like.
- laser processing for example, YAG laser
- electric discharge processing It can be performed by cutting the pipe by chemical etching, cutting, or the like.
- the X-ray marker is formed of a radiopaque material (a radiopaque material). This makes it possible to determine the position of the stent substrate under X-ray contrast.
- the X-ray opaque material for example, an X-ray opaque metal such as gold, platinum, a platinum iridium alloy, platinum, silver, stainless steel, or an alloy thereof is preferable.
- the X-ray marker may be a resin molded product containing an X-ray contrast material powder.
- the X-ray contrast material powder barium sulfate, bismuth subcarbonate, tungsten powder, the above-mentioned metal powder and the like can be used.
- the stent of the present invention is characterized in that a stent substrate is coated with the above-mentioned film.
- a stent substrate is coated with the above-mentioned film.
- the stent of the present invention is obtained by coating the above-mentioned film on the stent base material, the peripheral wall of the stent which does not only exert the cell growth inhibitory action at the contact portion of the film is digested. It has the function of permeating a liquid and digestive enzymes contained therein, but not permeating cancer cells (tumor cells). Accordingly, when the stent of the present invention is placed in the lumen of the stent, the stenosis of the body lumen caused by the growth of cancer cells beyond the peripheral wall of the stent is increased. While prevented, the flow of digestive juices and digestive enzymes is not impeded.
- the method of coating the above-mentioned film on the stent base material is not particularly limited, and may be simply wound around the stent base material, or may be fused with an adhesive, a solvent, or heat as needed. Alternatively, such means may be used.
- the stent of the present invention can be placed in the lumen of the stent in the body by using the same method as the conventional stent.
- the stent base material is made of a material having high elasticity such as a superelastic alloy
- the delivery catheter is contracted while the peripheral wall of the stent is contracted.
- the stent substrate is made of a material with poor elasticity, such as stainless steel
- the stent is fitted over the balloon of the norain catheter, transported to the place where it is to be placed, and then And expanding the peripheral wall of the stent to place the stent.
- the coated film may be stretched by utilizing the expansion force of the stent substrate.
- the digestive system stent of the present invention can be placed in any of the lumens of the digestive system body such as the bile duct, esophagus, duodenum, and large intestine. It is preferably used as a biliary stent that often reaches the splenic outlet.
- the stent of the present invention as a bile duct stent, even if the stent reaches the spleen outlet at the time of indwelling the bile duct, the spleen fluid and the digestive enzymes such as trypsin and lipase contained therein are distributed. Can prevent the onset of knee inflammation, etc.
- the cell lines used and their culture conditions are as follows.
- Cell line A Human gallbladder cancer cell line NOZ (Cell number: JCRB1033)
- Cell line B Human malignant gallbladder cancer cell line OCUG—l (Cell number: JCR B0191) All purchased from Human Science Promotion Foundation Research Resource Bank
- the cell line A (NOZ) was cultured at 37 ° C. and 5% CO in a William's E medium containing fetal calf serum (10% FBS) and 2 mM L-sodium glutamate.
- the cell line B (OCUG-1) was cultured at 37 ° C. and 5% CO in Dulbecco's modified Eagle's medium containing 10% FBS and 0.5 mM pyruvate. [0082] Approximately 1 ⁇ 10 4 cells per 1 ⁇ l were plated on a 24-well plate (Falcon 3047) ((incubation), and as a result, about 80% confluency was obtained the next day.
- the Dulbecco's modified Eagle's medium used was also purchased from Invitrogen Corporation, and William's E medium, L-glutamate sodium and pyruvate were obtained from ICN Biomedicals Inc. ) was used and the fetal serum used was purchased from JR H. (JRH Bioscience).
- Poly ⁇ -force prolatatatone (viscosity average molecular weight: 70,000, manufactured by Wako Pure Chemical Industries) and Cap resin (weight average molecular weight: 62,000, number average molecular weight: 21, 000), weight ratio of 10: 1 in black port formate solution in beam: a ( ⁇ concentration 0.27 wt 0/0) 6ml, was uniformly spread on a glass petri dish having a diameter of 10 cm.
- a high humidity air with a relative humidity of 70% is sprayed onto the liquid surface on the glass petri dish at a flow rate of 2L Zmin for 1 minute to obtain a film thickness of 1 to 2 m.
- Film A was obtained.
- the film A was observed at a magnification of 100 times using an optical microscope (BH2, manufactured by Olympus Corporation). As a result, it was confirmed that a porous structure having a honeycomb-like structure was formed.
- the average pore diameter of the pores constituting the porous structure was 3.5 ⁇ ⁇ , and the coefficient of variation of the pore diameter was 9%.
- the average pore diameter and the coefficient of variation of the pore diameter were determined by measuring the pore diameters of all the pores in the visual field of the microscope (100 / zm ⁇ 100 ⁇ m).
- Film B having a porous structure with a honeycomb-like structure was prepared in the same manner as in Example 1 except that the heat treatment was performed in an atmosphere of 24.0 ° C. in Example 2 and 25.0 ° C. in Example 3. Got C.
- Table 1 shows the thicknesses of the obtained films B and C, the average pore diameter of the pores constituting the porous structure, and the coefficient of variation of the pore diameter.
- 1, 2 polybutadiene (trade name: RB820 Films D, E, and F were obtained in the same manner as in Examples 1, 2, and 3, respectively, except for using JSR).
- Table 1 shows the thicknesses of the films DF, the average pore diameter of the pores constituting the porous structure, and the coefficient of variation of the pore diameter.
- Film G ⁇ was obtained in the same manner as in Examples 1 and 2, except that polyurethane (trade name: Milactran 385, manufactured by Nippon Milactran) was used as the resin instead of poly ⁇ -force prolatatatone.
- polyurethane trade name: Milactran 385, manufactured by Nippon Milactran
- Table 1 shows the thicknesses of the films G and H, the average pore diameter of the pores constituting the porous structure, and the coefficient of variation of the pore diameter.
- Each of the films A to K of Example 18 and Comparative Example 13 was placed in the William's E medium and Dulbecco's modified Eagle's medium, and the cell lines A and B were placed on the respective films. The cells were seeded and cultured under the above culture conditions.
- the cells are washed twice with Magnesium-free Dulbecco's phosphate buffer (Dainippon Pharmaceutical Co., Ltd.), and then stained with Wright's solution (Wako Pure Chemicals for blood staining) for 10 minutes. did.
- cell growth-inhibiting film of the present invention is different from cell line A: human gallbladder cancer cell line (NOZ) and cell line B: human malignant gallbladder cancer cell line (OCUG-1).
- NOZ human gallbladder cancer cell line
- cell line B human malignant gallbladder cancer cell line
- OCUG-1 human malignant gallbladder cancer cell line
- 1,2-polybutadiene (trade name: RB820, manufactured by JSR Corporation) and a Cap resin (weight average molecular weight: 62,000, number average molecular weight: 21,000) having a repeating unit represented by the above formula 1 6 ml of a solution (resin concentration: 0.27% by weight) dissolved in black mouth form at a weight ratio of 1: 1 was spread uniformly on a glass Petri dish having a diameter of 10 cm. Then, under an atmosphere of 23.0 ° C and a relative humidity of 40%, a high humidity air with a relative humidity of 70% is sprayed at a flow rate of 2LZmin onto the liquid surface on the glass petri dish for 1 minute to form a film having a thickness of 3-4. m of film L was obtained.
- Example 10 was repeated in the same manner as in Example 9 except that the test was performed in an atmosphere of 24.0 ° C. in Example 10 and 25.0 ° C. in Example 11. Films M and N were obtained. Table 3 shows the thicknesses of the obtained films M and N, the average pore diameter of the through-holes constituting the porous structure, and the coefficient of variation of the pore diameter.
- Films 0, P, and Q were prepared in the same manner as in Examples 9-1 1 except that polyurethane (trade name: Milactran E385, manufactured by Nippon Milactran) was used as the resin instead of 1,2-polybutadiene. Got. Observation of the obtained film O—Q with an optical microscope confirmed that a porous structure having a honeycomb structure was formed. Table 3 shows the film thicknesses of the films O-Q, the average pore diameter of the through-holes constituting the porous structure, and the coefficient of variation of the pore diameter.
- polyurethane trade name: Milactran E385, manufactured by Nippon Milactran
- a 1,2-polybutadiene / Cap resin used in Example 9 was mixed in a glass dish for 1 minute at a flow rate of 2 LZmin at a flow rate of 2 LZmin in an atmosphere of 23.0 ° C under an atmosphere of 23.0 ° C. Except that spraying on the liquid level above is changed to spraying high humidity air with a relative humidity of 70% and a flow rate of 5 LZmin for 1 minute on a glass petri dish at 28.0 ° C.
- Table 3 shows the thickness of the film T, the average pore diameter of the through-holes constituting the porous structure, and the coefficient of variation of the pore diameter.
- the polyurethane resin and the Cap resin used in Examples 12-14 were mixed in a 10: 1 weight ratio of chloropho Solution in Lum ( ⁇ concentration. 0 27 weight 0/0) to 6 ml, instead of being uniformly expanded on a glass petri dish having a diameter of 10 cm, a polyurethane ⁇ and Cap ⁇ 10: 1 weight ratio in black port solution in Holm: a ( ⁇ concentration. 0 27 wt 0/0) 10 ml, except for uniformly spread on a glass petri dish with a diameter of 10 cm, in the same manner as in example 12 Film U of Reference Example 2 was obtained.
- Table 3 shows the thickness of the film U, the average pore diameter of the through-holes constituting the porous structure, and the coefficient of variation of the pore diameter.
- Powdery trypsin was added to phosphate buffered saline (PBS) to prepare a 25 gZL trypsin PBS solution to prepare a trypsin test solution.
- a lipase PBS solution of 25 g / L was prepared using powdered lipase to prepare a lipase test solution.
- the cell line A (NOZ) is cultured under the culture conditions described above, the obtained NOZ is cultivated in PBS, and a cell suspension containing NOZ at a concentration of 1 ⁇ 10 6 [pieces Zml] is prepared.
- Test solution
- the cell line B (OCUG-1) was cultured under the above culture conditions, and the obtained OCUG-1 was added to PBS, and a cell suspension containing OCUG-1 at a concentration of 1 x 10 6 [pieces of Zml] was added. Prepare the solution and use OCU The test solution was G-1.
- Each of the films L1U prepared in Examples 9 to 14, Comparative Examples 4 and 5, and Reference Examples 1 and 2 was set in a filter holder having a diameter of 10 mm. The solution was dropped at a rate of 5 [mlZmin]. Ten minutes after the start of the dropping, the liquid permeated through the film was collected to obtain 10 ml of the permeated liquid. However, in the case of film S, no test liquid was obtained because all test liquids did not pass through the film.
- the digestion enzyme amount in the solution was measured using an ultraviolet-visible spectrophotometer CFASCO, V-530) as follows.
- a test solution (concentration: 25 gZL) of trypsin and lipase before passing through a film was diluted 100-fold with PBS, respectively, to obtain a concentration of 0.25 gZL, which was defined as a reduced concentration of 0.1 OlCo.
- a solution of trypsin and lipase having a reduced concentration of 0.009Co, 0.007Co, 0.005Co, and 0.004Co is prepared, and the absorption intensities thereof (trypsin: 278 nm, lipase: 274 nm) are measured.
- a calibration curve of the converted concentration absorption intensity was created.
- the absorption intensity of the trypsin solution was 0.23 Abs
- the absorption intensity of the lipase solution was 0.14 Abs.
- a cell growth-inhibiting film which exhibits an excellent cell growth-inhibiting action without using a physiologically active substance and is suitable for constituting a medical device
- a cell of the present invention Cell growth inhibition method using a growth inhibition film; A medical device coated with an anti-proliferative film, and (4) a digestive system stent that secures the lumen of the digestive system and allows the digestive juice and digestive enzymes contained therein to pass through, but not the cancer cells , are provided.
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04819437A EP1688155A4 (en) | 2003-11-28 | 2004-11-26 | CELL FORMATION INHIBITION FILM, MEDICAL INSTRUMENT AND ENDOPROTHESIS FOR DIGESTIVE ORGANS |
US10/580,648 US20070275156A1 (en) | 2003-11-28 | 2004-11-26 | Cell Growth Inhibiting Film, Medical Instrument and Digestive System Stent |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-399197 | 2003-11-28 | ||
JP2003399195A JP4610885B2 (ja) | 2003-11-28 | 2003-11-28 | 細胞増殖抑制フィルムおよび医療用具 |
JP2003-399195 | 2003-11-28 | ||
JP2003399197A JP4512351B2 (ja) | 2003-11-28 | 2003-11-28 | 消化器系ステント |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005051450A1 true WO2005051450A1 (ja) | 2005-06-09 |
Family
ID=34635630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/017572 WO2005051450A1 (ja) | 2003-11-28 | 2004-11-26 | 細胞増殖抑制フィルム、医療用具および消化器系ステント |
Country Status (3)
Country | Link |
---|---|
US (1) | US20070275156A1 (ja) |
EP (1) | EP1688155A4 (ja) |
WO (1) | WO2005051450A1 (ja) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006118248A1 (ja) * | 2005-04-28 | 2006-11-09 | Japan Science And Technology Agency | 細胞増殖抑制部材、細胞転移抑制部材、細胞増殖抑制方法、細胞転移抑制方法、積層フィルムおよび医療用具 |
US7833266B2 (en) | 2007-11-28 | 2010-11-16 | Boston Scientific Scimed, Inc. | Bifurcated stent with drug wells for specific ostial, carina, and side branch treatment |
US7931683B2 (en) | 2007-07-27 | 2011-04-26 | Boston Scientific Scimed, Inc. | Articles having ceramic coated surfaces |
US7938855B2 (en) | 2007-11-02 | 2011-05-10 | Boston Scientific Scimed, Inc. | Deformable underlayer for stent |
US7942926B2 (en) | 2007-07-11 | 2011-05-17 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US7951193B2 (en) | 2008-07-23 | 2011-05-31 | Boston Scientific Scimed, Inc. | Drug-eluting stent |
US7976915B2 (en) | 2007-05-23 | 2011-07-12 | Boston Scientific Scimed, Inc. | Endoprosthesis with select ceramic morphology |
US7981150B2 (en) | 2006-11-09 | 2011-07-19 | Boston Scientific Scimed, Inc. | Endoprosthesis with coatings |
US8002823B2 (en) | 2007-07-11 | 2011-08-23 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US8029554B2 (en) | 2007-11-02 | 2011-10-04 | Boston Scientific Scimed, Inc. | Stent with embedded material |
US8066763B2 (en) | 1998-04-11 | 2011-11-29 | Boston Scientific Scimed, Inc. | Drug-releasing stent with ceramic-containing layer |
US8067054B2 (en) | 2007-04-05 | 2011-11-29 | Boston Scientific Scimed, Inc. | Stents with ceramic drug reservoir layer and methods of making and using the same |
US8071156B2 (en) | 2009-03-04 | 2011-12-06 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8070797B2 (en) | 2007-03-01 | 2011-12-06 | Boston Scientific Scimed, Inc. | Medical device with a porous surface for delivery of a therapeutic agent |
US8187620B2 (en) | 2006-03-27 | 2012-05-29 | Boston Scientific Scimed, Inc. | Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents |
US8216632B2 (en) | 2007-11-02 | 2012-07-10 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US8221822B2 (en) | 2007-07-31 | 2012-07-17 | Boston Scientific Scimed, Inc. | Medical device coating by laser cladding |
US8231980B2 (en) | 2008-12-03 | 2012-07-31 | Boston Scientific Scimed, Inc. | Medical implants including iridium oxide |
US8287937B2 (en) | 2009-04-24 | 2012-10-16 | Boston Scientific Scimed, Inc. | Endoprosthese |
US8353949B2 (en) | 2006-09-14 | 2013-01-15 | Boston Scientific Scimed, Inc. | Medical devices with drug-eluting coating |
US8431149B2 (en) | 2007-03-01 | 2013-04-30 | Boston Scientific Scimed, Inc. | Coated medical devices for abluminal drug delivery |
US8574615B2 (en) | 2006-03-24 | 2013-11-05 | Boston Scientific Scimed, Inc. | Medical devices having nanoporous coatings for controlled therapeutic agent delivery |
US8771343B2 (en) | 2006-06-29 | 2014-07-08 | Boston Scientific Scimed, Inc. | Medical devices with selective titanium oxide coatings |
US8815275B2 (en) | 2006-06-28 | 2014-08-26 | Boston Scientific Scimed, Inc. | Coatings for medical devices comprising a therapeutic agent and a metallic material |
US8815273B2 (en) | 2007-07-27 | 2014-08-26 | Boston Scientific Scimed, Inc. | Drug eluting medical devices having porous layers |
US8900292B2 (en) | 2007-08-03 | 2014-12-02 | Boston Scientific Scimed, Inc. | Coating for medical device having increased surface area |
US8920491B2 (en) | 2008-04-22 | 2014-12-30 | Boston Scientific Scimed, Inc. | Medical devices having a coating of inorganic material |
US8932346B2 (en) | 2008-04-24 | 2015-01-13 | Boston Scientific Scimed, Inc. | Medical devices having inorganic particle layers |
US9284409B2 (en) | 2007-07-19 | 2016-03-15 | Boston Scientific Scimed, Inc. | Endoprosthesis having a non-fouling surface |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2009041352A1 (ja) * | 2007-09-25 | 2011-01-27 | 富士フイルム株式会社 | 多孔フイルムの製造方法、及び多孔フイルム、複合材料 |
JP2009084429A (ja) * | 2007-09-28 | 2009-04-23 | Fujifilm Corp | フィルム及びその製造方法 |
JP6343492B2 (ja) | 2013-07-09 | 2018-06-13 | 豊田合成株式会社 | 細胞培養用および癌細胞増殖抑制用の少なくとも一方の用途に用いるポリウレタン多孔質膜の製造方法 |
ES2762850T3 (es) | 2013-12-13 | 2020-05-26 | Vac Stent Medtec Ag | Stent de aspiración y sistema de stent para sellar una fuga |
DE202015007495U1 (de) | 2015-10-29 | 2017-01-31 | Pass Stanztechnik Ag | Wechsel-Umformwerkzeug |
JP6142042B1 (ja) | 2016-03-18 | 2017-06-07 | 株式会社村田製作所 | 有核細胞の濾過用フィルターおよびそれを用いた濾過方法 |
EP3476370B1 (en) | 2016-06-23 | 2023-02-15 | M.I.Tech Co., Ltd. | Multi-hole stent for digestive organs |
CN108379663B (zh) * | 2018-04-24 | 2023-05-26 | 中国人民解放军第四军医大学 | 一种多孔规则体支架材料中截留及富集细胞的装置和方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001149061A (ja) * | 1999-10-20 | 2001-06-05 | Creavis G Fuer Technol & Innov Mbh | 細胞増殖を阻害する性質を有する構造化表面、その製造法およびその使用 |
JP2001157574A (ja) * | 1999-11-30 | 2001-06-12 | Terumo Corp | ハニカム構造体およびその調製方法、ならびにその構造体を用いたフィルムおよび細胞培養基材 |
JP2001512354A (ja) | 1997-02-20 | 2001-08-21 | クック インコーポレーティッド. | 被覆された移植可能な医療器具 |
JP2001327609A (ja) | 2000-05-19 | 2001-11-27 | Terumo Corp | 生体内留置用ステント |
JP2002335949A (ja) | 2001-05-22 | 2002-11-26 | Inst Of Physical & Chemical Res | ハニカム構造体フィルムを用いた細胞の三次元組織培養法 |
JP2002347107A (ja) * | 2001-05-22 | 2002-12-04 | Inst Of Physical & Chemical Res | 延伸フィルムおよびそれを用いた細胞培養基材 |
JP2003102849A (ja) * | 2001-09-28 | 2003-04-08 | Terumo Corp | 生体内留置用ステント |
JP2003149096A (ja) | 2001-11-07 | 2003-05-21 | Fuji Photo Film Co Ltd | 血液濾過膜および方法 |
JP2004024616A (ja) * | 2002-06-26 | 2004-01-29 | Jsr Corp | 再狭窄の少ないステント |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5755788A (en) * | 1987-02-19 | 1998-05-26 | Rutgers, The State University | Prosthesis and implants having liposomes bound thereto and methods of preparation |
US6579314B1 (en) * | 1995-03-10 | 2003-06-17 | C.R. Bard, Inc. | Covered stent with encapsulated ends |
US6875386B1 (en) * | 1999-11-17 | 2005-04-05 | Isense Corp. | Neovascularization promoting membrane for bioimplants |
US6436132B1 (en) * | 2000-03-30 | 2002-08-20 | Advanced Cardiovascular Systems, Inc. | Composite intraluminal prostheses |
US20040111144A1 (en) * | 2002-12-06 | 2004-06-10 | Lawin Laurie R. | Barriers for polymeric coatings |
JP4579824B2 (ja) * | 2003-04-10 | 2010-11-10 | 帝人株式会社 | ハニカム構造を有する生分解性フィルム |
-
2004
- 2004-11-26 EP EP04819437A patent/EP1688155A4/en not_active Withdrawn
- 2004-11-26 US US10/580,648 patent/US20070275156A1/en not_active Abandoned
- 2004-11-26 WO PCT/JP2004/017572 patent/WO2005051450A1/ja active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001512354A (ja) | 1997-02-20 | 2001-08-21 | クック インコーポレーティッド. | 被覆された移植可能な医療器具 |
JP2001149061A (ja) * | 1999-10-20 | 2001-06-05 | Creavis G Fuer Technol & Innov Mbh | 細胞増殖を阻害する性質を有する構造化表面、その製造法およびその使用 |
JP2001157574A (ja) * | 1999-11-30 | 2001-06-12 | Terumo Corp | ハニカム構造体およびその調製方法、ならびにその構造体を用いたフィルムおよび細胞培養基材 |
JP2001327609A (ja) | 2000-05-19 | 2001-11-27 | Terumo Corp | 生体内留置用ステント |
JP2002335949A (ja) | 2001-05-22 | 2002-11-26 | Inst Of Physical & Chemical Res | ハニカム構造体フィルムを用いた細胞の三次元組織培養法 |
JP2002347107A (ja) * | 2001-05-22 | 2002-12-04 | Inst Of Physical & Chemical Res | 延伸フィルムおよびそれを用いた細胞培養基材 |
JP2003102849A (ja) * | 2001-09-28 | 2003-04-08 | Terumo Corp | 生体内留置用ステント |
JP2003149096A (ja) | 2001-11-07 | 2003-05-21 | Fuji Photo Film Co Ltd | 血液濾過膜および方法 |
JP2004024616A (ja) * | 2002-06-26 | 2004-01-29 | Jsr Corp | 再狭窄の少ないステント |
Non-Patent Citations (2)
Title |
---|
NISHI S. ET AL.: "Development of a novel highfunctional cavered stent with micropore and drug delivery performance", JAPANESE JOURNAL OF ARTIFICIAL ORGANS, vol. 29, no. 1, 2000, pages 257 - 263, XP002983654 * |
NISHIKAWA T. ET AL.: "Mesoscopic pattering of cell adhesive substrates as novel biofunctional interfaces", MATERIALS SCIENCE & ENGINEERING, C:BIOMIMETIC AND SUPRAMOLECULAR SYSTEMS, vol. C10, no. 1-2, 1999, pages 141 - 146, XP002983653 * |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8066763B2 (en) | 1998-04-11 | 2011-11-29 | Boston Scientific Scimed, Inc. | Drug-releasing stent with ceramic-containing layer |
WO2006118248A1 (ja) * | 2005-04-28 | 2006-11-09 | Japan Science And Technology Agency | 細胞増殖抑制部材、細胞転移抑制部材、細胞増殖抑制方法、細胞転移抑制方法、積層フィルムおよび医療用具 |
US8574615B2 (en) | 2006-03-24 | 2013-11-05 | Boston Scientific Scimed, Inc. | Medical devices having nanoporous coatings for controlled therapeutic agent delivery |
US8187620B2 (en) | 2006-03-27 | 2012-05-29 | Boston Scientific Scimed, Inc. | Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents |
US8815275B2 (en) | 2006-06-28 | 2014-08-26 | Boston Scientific Scimed, Inc. | Coatings for medical devices comprising a therapeutic agent and a metallic material |
US8771343B2 (en) | 2006-06-29 | 2014-07-08 | Boston Scientific Scimed, Inc. | Medical devices with selective titanium oxide coatings |
US8353949B2 (en) | 2006-09-14 | 2013-01-15 | Boston Scientific Scimed, Inc. | Medical devices with drug-eluting coating |
US7981150B2 (en) | 2006-11-09 | 2011-07-19 | Boston Scientific Scimed, Inc. | Endoprosthesis with coatings |
US8070797B2 (en) | 2007-03-01 | 2011-12-06 | Boston Scientific Scimed, Inc. | Medical device with a porous surface for delivery of a therapeutic agent |
US8431149B2 (en) | 2007-03-01 | 2013-04-30 | Boston Scientific Scimed, Inc. | Coated medical devices for abluminal drug delivery |
US8067054B2 (en) | 2007-04-05 | 2011-11-29 | Boston Scientific Scimed, Inc. | Stents with ceramic drug reservoir layer and methods of making and using the same |
US7976915B2 (en) | 2007-05-23 | 2011-07-12 | Boston Scientific Scimed, Inc. | Endoprosthesis with select ceramic morphology |
US8002823B2 (en) | 2007-07-11 | 2011-08-23 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US7942926B2 (en) | 2007-07-11 | 2011-05-17 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US9284409B2 (en) | 2007-07-19 | 2016-03-15 | Boston Scientific Scimed, Inc. | Endoprosthesis having a non-fouling surface |
US8815273B2 (en) | 2007-07-27 | 2014-08-26 | Boston Scientific Scimed, Inc. | Drug eluting medical devices having porous layers |
US7931683B2 (en) | 2007-07-27 | 2011-04-26 | Boston Scientific Scimed, Inc. | Articles having ceramic coated surfaces |
US8221822B2 (en) | 2007-07-31 | 2012-07-17 | Boston Scientific Scimed, Inc. | Medical device coating by laser cladding |
US8900292B2 (en) | 2007-08-03 | 2014-12-02 | Boston Scientific Scimed, Inc. | Coating for medical device having increased surface area |
US8216632B2 (en) | 2007-11-02 | 2012-07-10 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US7938855B2 (en) | 2007-11-02 | 2011-05-10 | Boston Scientific Scimed, Inc. | Deformable underlayer for stent |
US8029554B2 (en) | 2007-11-02 | 2011-10-04 | Boston Scientific Scimed, Inc. | Stent with embedded material |
US7833266B2 (en) | 2007-11-28 | 2010-11-16 | Boston Scientific Scimed, Inc. | Bifurcated stent with drug wells for specific ostial, carina, and side branch treatment |
US8920491B2 (en) | 2008-04-22 | 2014-12-30 | Boston Scientific Scimed, Inc. | Medical devices having a coating of inorganic material |
US8932346B2 (en) | 2008-04-24 | 2015-01-13 | Boston Scientific Scimed, Inc. | Medical devices having inorganic particle layers |
US7951193B2 (en) | 2008-07-23 | 2011-05-31 | Boston Scientific Scimed, Inc. | Drug-eluting stent |
US8231980B2 (en) | 2008-12-03 | 2012-07-31 | Boston Scientific Scimed, Inc. | Medical implants including iridium oxide |
US8071156B2 (en) | 2009-03-04 | 2011-12-06 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8287937B2 (en) | 2009-04-24 | 2012-10-16 | Boston Scientific Scimed, Inc. | Endoprosthese |
Also Published As
Publication number | Publication date |
---|---|
US20070275156A1 (en) | 2007-11-29 |
EP1688155A1 (en) | 2006-08-09 |
EP1688155A4 (en) | 2008-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005051450A1 (ja) | 細胞増殖抑制フィルム、医療用具および消化器系ステント | |
JP4512351B2 (ja) | 消化器系ステント | |
JP4610885B2 (ja) | 細胞増殖抑制フィルムおよび医療用具 | |
JP4662556B2 (ja) | 治療薬デリバリー制御に関する相溶性ポリマーブレンド含有埋め込み又は挿入可能医療器具 | |
JP5213270B2 (ja) | 制御された治療薬送達のためのナノ多孔質コーティングを含む医療デバイス | |
EP1965842B1 (en) | Medical devices having multiple charged layers | |
CA2570444C (en) | Absorbable stent comprising coating for controlling degradation and maintaining ph neutrality | |
JP5270617B2 (ja) | ブロックコポリマを含む薬物送達構成体及び医療器具 | |
JP2011525849A (ja) | 治療剤を含む医療機器 | |
JP5824794B2 (ja) | 動脈瘤治療用ステント | |
JP2008522752A (ja) | 制御された治療剤送達のための蒸着ナノポーラス被覆を有する医療装置 | |
EP2205292B1 (en) | Therapeutic agent-eluting medical devices having textured polymeric surfaces | |
JPWO2006027994A1 (ja) | 生体留置用ステント | |
EP1909861A2 (en) | Therapeutic pastes for medical device coating | |
JP2008520349A (ja) | 医療デバイスのための治療剤駆動層 | |
WO2006054584A1 (ja) | バイオフィルム形成阻害剤及び治療用器具 | |
JPWO2006118248A1 (ja) | 細胞増殖抑制部材、細胞転移抑制部材、細胞増殖抑制方法、細胞転移抑制方法、積層フィルムおよび医療用具 | |
JP2005530561A (ja) | 薬剤送達用シリコーン混合物及び複合体 | |
BRPI0617894A2 (pt) | método para produção de um dispositivo endovascular revestido | |
KR102123020B1 (ko) | 생체 재료의 패터닝과 이의 전사를 통한 인공 혈관 내벽의 생체 특성 증진 | |
JP2002172159A (ja) | 体内埋め込み医療器具 | |
JP2005168937A (ja) | ステント | |
US11208720B2 (en) | Method for treatment medical devices made from nickel-titanium (NiTi) alloys | |
WO2006027994A1 (ja) | 生体留置用ステント | |
KR20200107007A (ko) | 약물 방출 스텐트 및 이의 제조 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004819437 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200480041090.3 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2004819437 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10580648 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10580648 Country of ref document: US |